Q-omics provides the consensus-scored HSD11B2 profile across patient tissues and cancer cell-line models. HSD11B2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HSD11B2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, HSD11B2 RNA expression shows 19,005 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where HSD11B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD11B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD11B2 survival associations across molecular data types. HSD11B2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD11B2 RNA expression–survival associations across cancer types. High HSD11B2 expression shows unfavorable associations in ACC, UVM and SKCM, but favorable associations in KIRC, OV and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HSD11B2 RNA expression.
This table summarizes HSD11B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSD11B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD11B2 shows lower tumor expression in KIRC, KIRP, THCA and COAD and higher tumor expression in LIHC and BRCA. The KIRC box plot shows higher HSD11B2 RNA expression in normal versus tumor tissue (log2 FC = −4.589, t-test p < 0.001).
This table shows molecular features associated with HSD11B2 in patient tissues and cancer cell lines. In patient samples, HSD11B2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSD11B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
